Compare FCUV & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FCUV | GOVX |
|---|---|---|
| Founded | 2012 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9M | 4.6M |
| IPO Year | N/A | N/A |
| Metric | FCUV | GOVX |
|---|---|---|
| Price | $5.06 | $1.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $103.00 |
| AVG Volume (30 Days) | 30.6K | ★ 163.9K |
| Earning Date | 03-26-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $387,457.00 | ★ $3,353,560.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 8.52 |
| 52 Week Low | $4.91 | $1.63 |
| 52 Week High | $61.40 | $47.13 |
| Indicator | FCUV | GOVX |
|---|---|---|
| Relative Strength Index (RSI) | 74.17 | 38.61 |
| Support Level | $4.91 | $2.51 |
| Resistance Level | $6.19 | $2.76 |
| Average True Range (ATR) | 0.86 | 0.26 |
| MACD | 0.57 | -0.18 |
| Stochastic Oscillator | 36.50 | 3.93 |
Focus Universal Inc offers smart devices, IoT products, and patented products and technologies for 5G telecommunications and network security. It is focused on commercializing its universal smart technology and financial reporting software. Its product line includes various digital, analog, and quantum light meters and filtration products, the Ubiquitor universal smart device, SEC Financial Reporting Software, and other smart devices and sensors. The company's reportable segments are Corporate and IoT, which derives maximum revenue, and Perfecular and Lusher. The Corporate and IoT segment includes its LED and IoT installation and management business (under Smart AVX), specializing in LED and display systems, home theaters, lighting control, automation, and integration.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.